Literature DB >> 24905187

Measuring and Statistically Testing the Size of the Effect of a Chemical Compound on a Continuous In-Vitro Pharmacological Response Through a New Statistical Model of Response Detection Limit.

Francisco J Diaz1, Peter R McDonald, Abraham Pinter, Rathnam Chaguturu.   

Abstract

Biomolecular screening research frequently searches for the chemical compounds that are most likely to make a biochemical or cell-based assay system produce a strong continuous response. Several doses are tested with each compound and it is assumed that, if there is a dose-response relationship, the relationship follows a monotonic curve, usually a version of the median-effect equation. However, the null hypothesis of no relationship cannot be statistically tested using this equation. We used a linearized version of this equation to define a measure of pharmacological effect size, and use this measure to rank the investigated compounds in order of their overall capability to produce strong responses. The null hypothesis that none of the examined doses of a particular compound produced a strong response can be tested with this approach. The proposed approach is based on a new statistical model of the important concept of response detection limit, a concept that is usually neglected in the analysis of dose-response data with continuous responses. The methodology is illustrated with data from a study searching for compounds that neutralize the infection by a human immunodeficiency virus of brain glioblastoma cells.

Entities:  

Keywords:  Biomolecular screening; Constrained least squares; Dose–response effects; Effect size; Hill equation; Logit transformation; Median-effect equation; Michaelis–Menten equation; Nonlinear regression; Scaled beta distribution

Mesh:

Substances:

Year:  2015        PMID: 24905187      PMCID: PMC5821445          DOI: 10.1080/10543406.2014.920871

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  5 in total

Review 1.  Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors:  Ting-Chao Chou
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 2.  The Hill equation: a review of its capabilities in pharmacological modelling.

Authors:  Sylvain Goutelle; Michel Maurin; Florent Rougier; Xavier Barbaut; Laurent Bourguignon; Michel Ducher; Pascal Maire
Journal:  Fundam Clin Pharmacol       Date:  2008-12       Impact factor: 2.748

3.  Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays.

Authors:  Francisco J Diaz; Peter R McDonald; Anuradha Roy; Byron Taylor; Ashleigh Price; Jessica Hall; Brian S J Blagg; Rathnam Chaguturu
Journal:  Comb Chem High Throughput Screen       Date:  2013-03       Impact factor: 1.339

4.  V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.

Authors:  C P Krachmarov; S C Kayman; W J Honnen; O Trochev; A Pinter
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

5.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

  5 in total
  1 in total

1.  Rapid Screening of Active Components with an Osteoclastic Inhibitory Effect in Herba epimedii Using Quantitative Pattern-Activity Relationships Based on Joint-Action Models.

Authors:  Xiao-Yan Yuan; Meng Wang; Sheng Lei; Qian-Xu Yang; Yan-Qiu Liu
Journal:  Molecules       Date:  2017-10-19       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.